Hypertriglyceridemia. Uncontrolled dyslipidemias. Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.Cigarette smoking increases risk of serious cardiovascular events.Increased risk of cardiovascular events (eg, stroke, MI) esp. Tri-Sprintec ® (norgestimate and ethinyl estradiol tablets USP) is estrogen/progestin COC, indicated for use by women to prevent pregnancy. Although NGMN and its metabolites inhibit a variety of P450 enzymes in human liver microsomes, under the recommended dosing regimen, the The metabolites of NGMN and EE are eliminated by renal and fecal pathways. Norgestimate 0.18mg, ethinyl estradiol 35mcg (7 tabs); norgestimate 0.215mg, ethinyl estradiol 35mcg (7 tabs); norgestimate 0.25mg, ethinyl estradiol 35mcg (7 tabs); inert (7 tabs).Moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche and are unresponsive to topical anti-acne medications.High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Diabetes.


Three Ways to Remember in What Order to Take the PillsWhat should I do if I miss any Tri-Sprintec pills?

Tell your A small proportion of women will have adverse lipid changes while on COCs. Be ready to tell or show what was

Use of this product before menarche is not indicated.There was no significant difference between Tri-Sprintec Tablets and placebo in mean change in total lumbar spine (L1-L4) and total hip bone mineral density between baseline and Cycle 13 in 123 adolescent females with anorexia nervosa in a double-blind, placebo-controlled, multicenter, one-year treatment duration clinical trial for the Intent To Treat (ITT) population.Tri-Sprintec has not been studied in postmenopausal women and is not indicated in this population.The pharmacokinetics of Tri-Sprintec has not been studied in subjects with hepatic impairment. These highlights do not include all the information needed to use Tri-Sprintec safely and effectively. Prediabetes.

If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.In clinical trials of Tri-Sprintec, the frequency and duration of breakthrough bleeding and/or spotting was assessed in 4,826 patients (35,546 evaluable cycles). At the end of 6 months, the mean total lesion count changed from 55 to 31 (42% reduction) in patients treated with Tri-Sprintec and from 54 to 38 (27% reduction) in patients similarly treated with placebo. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking Tri-Sprintec.The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:Adverse reactions commonly reported by COC users are:Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.The safety of Tri-Sprintec was evaluated in 4,826 healthy women of child-bearing potential who participated in 6 clinical trials and received at least 1 dose of Tri-Sprintec for contraception. 2, sodium bicarbonate and sodium carbonate), lactose monohydrate, magnesium stearate, and pregelatinized corn starchBlue pill: anhydrous lactose, FD&C blue no.
May need dose adjustment of thyroid hormones. Take subsequent active tablets once daily at the same time each day for a total of 21 days.

Day 1 Start: Take first active tablet without regard to meals on the first day of menses.

Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded.

Sprintec is the same dose in every pill, tri … Close more info about TRI-SPRINTEC Tri-Sprintec and Pregnancy; Indications for use .

Tri-Sprintec ® (norgestimate and ethinyl estradiol tablets USP) is estrogen/progestin COC, indicated for use by women to prevent pregnancy. Call your doctor or get medical